17 results about "Nonhuman animal" patented technology

The application provides a method for constructing a spontaneous esophageal precancerous lesion or esophageal cancer non-human animal model and application thereof. The non-human animal model of spontaneous esophageal precancerous lesion or esophageal cancer is obtained by deleting the expression of Trp53 and Cdkn2a in the non-human animal. The non-human animal model prepared by the application can be used as an ideal animal model for screening drug candidates, evaluating the therapeutic effect of drugs, evaluating the toxicological effect of drugs and researching the pathogenesis of esophageal precancerous lesion or esophageal cancer.

The application provides a construction system and device of a non-human animal model of tension pneumothorax, and the system comprises: a fixing unit for fixing the non-human animal; a first processing unit for puncturing a puncture needle to the parietal pleura, making a guide wire pass through the needle cavity of the puncture needle to enter the pleural cavity, and withdrawing the puncture needle; a second processing unit for inserting a catheter along the guide wire to make the catheter enter the pleural cavity, pulling out the guide wire, and fixing the catheter; a third processing unit for unidirectional air injection into the pleural cavity through the catheter; and a fourth processing unit for monitoring the range of pneumothorax, determining that the non-human animal model of tension pneumothorax is obtained when the lung sliding of the injection side chest is greater than or equal to 4 / 6 area and lung points are observed, stopping air injection, and obtaining the non-human animal model of tension pneumothorax. The construction success rate of the application is 100%, the construction process is rapid, repeatable and objective in determination, and the application can provide a rapid and repeatable platform for diagnostic research, decompression technology evaluation and training.

Embodiments of the invention encompass identification and characterization of microbiota having potential or demonstrated therapeutic effects for certain conditions in certain non-human animals. In some embodiments, the identification and characterization of microbiota may include identifying and characterizing the microbiota of potential donors, characterizing the potential donors, and identifying potentially therapeutic microbiota based on analysis of such data from multiple individuals. In some embodiments, the identification and characterization of microbiota may include testing, that is, administering microbiota of potential donors to animals suffering from a disease or condition, documenting any therapeutic response, and optionally identifying and characterizing the microbiota of recipients before and after treatment, and optionally identifying demonstrated therapeutic microbiota. Embodiments of the invention encompass compositions comprising the microbiotia, including solid oral compositions, methods of making these compositions, and methods of treatment of non-human animals suffering from various diseases and conditions with these compositions.

A nonhuman animal having a chimeric organ including a foreign cell in a body thereof.

The present invention provides non-human animals expressing human CFB protein or chimeric (e.g., humanized) CFB protein and methods for using the same. The present invention further provides a non-human animal genome, a humanized CFB gene, and cells, tissues, organs, or non-human animals containing the non-human animal genome and the humanized CFB gene. The non-human animals obtained in this application successfully express human CFB protein or humanized CFB protein, which can be cleaved by CFD, bind to C3b, and exert similar effects in the human body. Furthermore, the non-human animals obtained in this application have complete renal function, normal blood biochemical indicators, and, more remarkably, do not exhibit the potential diseases observed in other transgenic mice known in this art.

Compositions, assays, methods, diagnostic methods, kits, and diagnostic kits are disclosed for the specific and differential detection of SARS-COV-2 and / or other viruses from samples, including veterinary samples, clinical samples, food samples, forensic sample, environmental samples (e.g., obtained from soil, garbage, sewage, air, water, food processing and manufacturing surfaces, or likewise), or biological sample obtained from a human or non-human animal.

The present invention provides a genetically modified non-human animal or the like that functionally lacks an endogenous ABCB1 gene and that functionally expresses the human ABCB1 gene, the genetically modified non-human animal or the like retaining a DNA construct for functionally expressing the human ABCB1 gene, wherein the DNA construct includes a coding sequence for the human ABCB1 gene, a CAR / PXR response element present in the 5' promoter region of the human ABCB1 gene, at least one intron of the human ABCB1 gene, and a sequence of the enhancer region present at the 3' end side of the human ABCB1 gene, and the DNA construct does not include at least a portion of the coding sequence for the human ABCB4 gene or includes only a portion of the human RUNDC3B gene.

Described herein is the discovery that neither the nuclear localization signal (NLS) nor the prion-like domain (PLD) of TDP-43 is necessary for embryonic stem cell culture and differentiation into motor neurons in vitro. The ability of ES cells to express these TDP-43 mutants and differentiate into motor neurons that exhibit an ALS-like phenotype whereby the TDP-43 mutants redistribute to and aggregate in the cytoplasm and fail to regulate cryptic exon splicing allows these cells to act as a model of TDP-43 proteinopathy for the testing of candidate therapeutic agents that may resolve such proteinopathy. Additionally, these ES cells may be used to successfully generate non-human animals, e.g., mice, that also exhibit hallmark symptoms of ALS and that may be used in testing candidate agents useful in treating TDP-43 proteinopathies.

To provide novel compounds for use in the treatment or prevention of cancer and other proliferative conditions. [Solution] The present invention relates to novel compounds for use in the treatment or prevention of cancer and other proliferative conditions, characterized, for example, by cells expressing cytochrome P450 1B1 (CYP1B1) and its allele variants. The present invention also provides pharmaceutical compositions comprising one or more such compounds for use in medical therapies, for example, in the treatment or prevention of cancer or other proliferative conditions, as well as methods for treating cancer or other conditions in human or non-human animal patients. The present invention also provides methods for identifying novel compounds for use in the treatment or prevention of cancer and other proliferative conditions, characterized, for example, by cells expressing CYP1B1 and its allele variants. The present invention also provides methods for determining the efficacy of the compounds of the present invention in cancer treatment.

Genetically modified non-human animals that express a human or chimeric (e.g., humanized)ERBB, and methods of use thereof are disclosed.

The present invention relates to a composition for the nutrition or drink of a non-human animal comprising the combination of spirulina and Ascophyllum nodosum. It further relates to the use of this composition for improving the zootechnical performance of non-human animals.

The disclosure provides, in various embodiments, non-human animals that comprise a human immune cell engraftment and / or functional human immune system. The disclosure also provides, in various embodiments, methods of generating said non-human animals. The disclosure also provides, in various embodiments, methods of determining immunogenicity of antigens or an immunogenic fragment thereof or antigenic therapies and / or identifying agents that modulate immune response.

The present invention addresses the problem of providing a non-human animal that expresses the corisin peptide. The problem is solved by a non-human animal that includes cells that include an expression cassette that includes a corisin coding sequence.

Disclosed embodiments provide a system and method for animal-to-human translation. Disclosed embodiments can accept multimodal non-human animal communication data as input, such as vocalizations, gestures, brainwaves, and / or biometric indicators, and apply a machine-learning enabled debate-based oversight approach for determining a likely translation outcome. Disclosed embodiments perform a debate-based oversight process to obtain a decision on one or more meanings for received non-human animal communication data. The one or more meanings are associated with a human interpretation. A cross-species operation is performed based on the human interpretation. The cross-species operation can include rendering and / or presenting a translation on an output device such as an electronic display and / or audio speaker. The cross-species operation can include issuing a robot control command based on the human interpretation.

This document relates to methods and materials involved in producing antibodies (e.g., single domain antibody (sdAbs) and / or heavy chain only antibodies) having one or two chimeric heavy chains. For example, (A) genetically engineered non-human animals (e.g., genetically engineered mice) having the ability to produce an antibody having one or two chimeric heavy chains that include (1) a non-human Ig heavy chain constant domain (CH) 2 and / or a non-human CH3 domain and (2) a VH domain such as a VH domain set forth in any one of SEQ ID NOs:74-87. (B) genetically engineered non-human animals (e.g., genetically engineered mice) having the ability to produce antibody-like molecules that include (1) a non-human heavy chain constant (CH) 2 domain and / or a non-human CH3 domain (e.g., endogenous CH2 and / or CH3 domains) and (2) a TCR variable domain (e.g., a human TCR variable domain). (C) genetically engineered non-human animals (e.g., genetically engineered mice) having the ability to produce antibody-like molecules that include (a) a first amino acid sequence of a FN3 polypeptide (e.g., a 10FN3 polypeptide). (b) a human Ig variable D domain, (c) a second amino acid sequence of a FN3 polypeptide (e.g., a 10FN3 polypeptide), and (d) a non-human Ig heavy chain CH2 domain and / or a non-human CH3 domain (e.g., endogenous Ig CH2 and / or CH3 domains), (D) genetically engineered non-human animals (e.g., genetically engineered mice) having the ability to produce an antibody having one or two chimeric heavy chains that include (a) a non-human Ig heavy chain constant domain (CH) 2 and / or a non-human CH3 domain and (b) a variable region that includes a human JH domain (e.g., a human JH3 domain or a human JH4 domain) lacking all or at least one tryptophan amino acid residue(s), and (E) genetically engineered non-human animals (e.g., genetically engineered mice) having the ability to produce an antibody having a modified heavy chain including (a) a non-human CH2 domain and / or a non-human CH3 domain (e.g., endogenous CH2 and / or CH3 domains) and (b) a variable region that includes a human VH domain having a FR2 containing one, two, three, four, or more amino acid are provided. In addition, chimeric non-human animals (e.g., mice) generated from an embryo having (a) a first cell having one or more genomic modifications that prevent the first cell (and cells derived from the first cell) from producing immunoglobulins and (b) a second cell having an IgH locus that includes an exogenous nucleic acid sequence encoding a heavy chain variable region of an antibody of interest such that the chimeric non-human animal produces heavy chain antibodies containing the heavy chain variable region of the antibody of interest in addition to one or more variants of those heavy chain antibodies that underwent in vivo affinity maturation are provided.

The present disclosure provides, inter alia, a genetically modified non-human animal whose germline genome comprises a modified endogenous immunoglobulin κ light chain locus comprising a single rearranged human immunoglobulin λ light chain variable region operably linked to a non-human Cλ gene segment, the single rearranged human immunoglobulin λ light chain variable region comprising a human Vλ gene segment and a human Jλ gene segment. All immunoglobulin λ light chains expressed by B cells of the genetically modified non-human animal comprise a human immunoglobulin λ light chain variable domain expressed from a single rearranged human immunoglobulin λ light chain variable region or a somatically hypermutated version thereof. Such animals, tissues from such animals, and cells from such animals represent effective platforms for generating antibodies, e.g., bispecific antibodies.